0001567619-22-014909.txt : 20220803 0001567619-22-014909.hdr.sgml : 20220803 20220803213949 ACCESSION NUMBER: 0001567619-22-014909 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220801 FILED AS OF DATE: 20220803 DATE AS OF CHANGE: 20220803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Garren Hideki CENTRAL INDEX KEY: 0001854126 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35676 FILM NUMBER: 221134343 MAIL ADDRESS: STREET 1: C/O PROTHENA BIOSCIENCES INC STREET 2: 331 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO CENTRAL INDEX KEY: 0001559053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 BUSINESS PHONE: 011-353-1-236-2500 MAIL ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 FORMER COMPANY: FORMER CONFORMED NAME: Prothena Corp plc DATE OF NAME CHANGE: 20121102 FORMER COMPANY: FORMER CONFORMED NAME: Neotope Corp Ltd DATE OF NAME CHANGE: 20120926 4 1 doc1.xml FORM 4 X0306 4 2022-08-01 0 0001559053 PROTHENA CORP PUBLIC LTD CO PRTA 0001854126 Garren Hideki C/O PROTHENA BIOSCIENCES INC 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Ordinary Shares, par value $0.01 per share 2022-08-01 4 M 0 4000 24.90 A 4000 D Ordinary Shares, par value $0.01 per share 2022-08-01 4 S 0 4000 30.52 D 0 D Stock Option (Right to Buy) 24.9 2022-08-01 4 M 0 4000 0 D 2031-04-05 Ordinary Shares 4000 238000 D The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Michael Malecek, as attorney-in-fact for Hideki Garren 2022-08-03